Abstract
Continued Interest in Developing Alpha-7 Nicotinic Agonist Drugs for Treating Cognitive Deficits in Patients with Schizophrenia
Author(s): Peter F. BuckleyEnVivo Pharmaceuticals has initiated a clinical safety study of an alpha-7 nicotinic agonist (EVP-6124) in twenty patientstreatedwith a second-generation antipsychotic medication. EVP-6124 is a potent full agonist at the alpha-7 nicotinic receptor.